One of the most important cytokines involved in immune response regulation is interleukin 2 (IL-2), a potent activator of the proliferation and function of T lymphocytes and natural killer cells. The mechanisms by which the effects of IL-2 are propagated within cells are not understood. While the binding of IL-2 to its receptor was recently shown to lead to the activation of two kinases, Jak-1 and Jak-3, subsequent steps in the signaling pathway to the nucleus that lead to the activation of specific genes had not been characterized. Since many cytokines that activate Jak kinases also lead to the tyrosine phosphorylation and activation of members of the Stat family of transcription factors, the ability of IL-2 to trigger Stat phosphorylation was examined. Exposure The human immune system combines elements of both an antigen-restricted response by T and B lymphocytes and a less restricted response by natural killer (NK) cells. A combination of specific antigen recognition and a general growth signal is necessary for the activation of lymphocytes. The regulation of NK cell proliferation and cytotoxicity is less well understood but depends, in part, on the presence of certain cytokines. One of the most important growth and activation signaling molecules in both of these systems is interleukin-2 (IL-2), a 15-kDa glycoprotein originally identified as a T-cell growth factor (1) which binds to a tripartite receptor (2). Whereas the a chain of the IL-2 receptor is necessary only for high affinity binding of the ligand, the f3 and y chains appear to be involved in transmitting the signals necessary for IL-2-dependent cellular responses (3, 4). It is not known how the binding of IL-2 to its receptor leads to lymphocyte proliferation. The IL-2 receptor can associate with phosphatidylinositol 3-kinase (5), and can lead to increased phosphorylation of inositides. By a mechanism that is not yet elucidated, IL-2 interaction with its receptor also leads to the activation of S6 kinase (6, 7), p56Ick (8), p53/p56lYn (9), Ras (10), and Raf (11, 12) , and the transcription of a number of immediate early genes (13-15).
The human immune system combines elements of both an antigen-restricted response by T and B lymphocytes and a less restricted response by natural killer (NK) cells. A combination of specific antigen recognition and a general growth signal is necessary for the activation of lymphocytes. The regulation of NK cell proliferation and cytotoxicity is less well understood but depends, in part, on the presence of certain cytokines. One of the most important growth and activation signaling molecules in both of these systems is interleukin-2 (IL-2), a 15-kDa glycoprotein originally identified as a T-cell growth factor (1) which binds to a tripartite receptor (2) . Whereas the a chain of the IL-2 receptor is necessary only for high affinity binding of the ligand, the f3 and y chains appear to be involved in transmitting the signals necessary for IL-2-dependent cellular responses (3, 4) . It is not known how the binding of IL-2 to its receptor leads to lymphocyte proliferation. The IL-2 receptor can associate with phosphatidylinositol 3-kinase (5) , and can lead to increased phosphorylation of inositides. By a mechanism that is not yet elucidated, IL-2 interaction with its receptor also leads to the activation of S6 kinase (6, 7), p56Ick (8) , p53/p56lYn (9) , Ras (10) , and Raf (11, 12) , and the transcription of a number of immediate early genes (13) (14) (15) .
It is known that the ,B and y subunits of the IL-2 receptor share similarity with other receptor components of the hematopoietic receptor superfamily, many of whose members bind to and activate Jak kinases (16) . Recently it has been shown that Jak-3 and Jak-1 are phosphorylated on tyrosine residues and show enhanced kinase activity in vitro in response to IL-2 (17) (18) (19) . Activation of the Jak kinases is often accompanied by the phosphorylation on tyrosine residues of a group of cytoplasmic proteins termed Stats. These proteins were initially identified by virtue of their role in signaling in response to interferon (IFN) (20, 21) . Statl is produced as two isoforms, a 91-kDa form (Statla) and an 84-kDa form that lacks the last 38 amino acids (Statl,B) (22) . Although both of these proteins can bind to a common DNA element, only Statla can activate transcription (23) . Upon treatment with IFN-a, both of these proteins, as well as a distantly related 113-kDa protein (Stat2), become tyrosine phosphorylated, translocate to the nucleus, and form a complex that can bind a distinct DNA sequence and activate transcription (20) . More recently, new members of this family have been described, including Stat3 (24, 25) , Stat4 (25, 26) , Stat5 (27) , and Stat6 (28) . It is likely that there are other members of this family whose expression may be tissue restricted. In general, the Stat proteins are located in the cytoplasm prior to stimulation. Addition of the appropriate extracellular stimulus leads to Stat protein phosphorylation on tyrosine, translocation to the nucleus, binding to specific DNA sequences, and the modulation of transcription. The present study demonstrates that both Stat proteins and Stat-related proteins are activated in response to IL-2 treatment of T lymphocytes or NK cells. These findings delineate an IL-2-signaling pathway from the receptor to the nucleus.
MATERIALS AND METHODS
Reagents. Human IFN-a was provided by Hoffmann-La Roche. Phytohemagglutinin (PHA) was purchased from Burroughs Wellcome. Recombinant human IL-2 (specific activity 1.05 x 107 units/mg) was kindly provided by Amgen. Antibodies to Stat4, -5, and -6 were purchased from Transduction Laboratories (Lexington, KY).
Antibody Generation. A peptide was synthesized that contained amino acids 694-705 of mouse Statl, with phosphotyrosine in position 701, and rabbits were immunized with a peptide-bovine serum albumin conjugate. Other antibodies were raised to glutathione S-transferase fusion proteins containing the indicated region of a given Stat protein as described Proc. Natl. Acad. Sci. USA 92 (1995) twice in phosphate-buffered saline (PBS; 137 mM NaCl/2.7 mM KC/10 mM Na2HPO4/1.8 mM KH2PO4, pH 7.4), and resuspended in medium lacking IL-2 for 8-15 h prior to stimulation. SK-MEL-28 cells were grown in DMEM containing 10% fetal bovine serum.
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll/diatrizoate gradient centrifugation from cytopheresis buffy coat obtained from healthy donors. Activated T cells were prepared by culturing PBMC in medium containing 2.5 ,g of PHA per ml and 50 units of IL-2 per ml for 7-12 days. Flow cytometry revealed that at least 93% of the cellswere T cells. Culture medium was RPMI 1640 supplemented with 15% fetal bovine serum, 2 mM L-glutamine, and 1 mM sodium pyruvate.
Whole-Cell Extracts. Following stimulation, cells were placed on ice and washed twice with cold PBS. Protein was extracted by resuspending the cells to a density of 105 cells per ,ul in extraction buffer (50 mM Tris-HCl, pH 8.0/250 mM NaCl/0.5% Nonidet P-40/1 mM sodium orthovanadate/10 ,ug of phenylmethylsulfonyl fluoride per ml/10 ,ug of aprotinin per ml/10 Atg of leupeptin per ml) on ice with occasional vortexing for 15 min. Insoluble material was removed by centrifugation at 12,000 x g for 5 min at 4°C. Immunoprecipitation was performed as described (21) .
Western Blotting. Protein samples were separated by SDS/ PAGE on a 7% polyacrylamide gel and then transferred to nitrocellulose. The membranes were blocked and then incubated with primary antibody diluted 1:4000. After being washed, the blot was incubated with secondary antiserum conjugated to horseradish peroxidase (Calbiochem) diluted 1:8000. Antibody binding was detected by chemiluminescence. Anti-phosphotyrosine Western blots were performed by using PY20 (ICN) and 4G10 (Upstate Biotechnology, Lake Placid, NY) anti-phosphotyrosine antibodies.
DNA-Binding Assay. Nuclear extracts were prepared as described (22) . Two microliters of nuclear extract was mixed 1 ). Upon treatment with IFN-a, an additional band of apparent molecular mass 92 kDa can be seen. This represents the Tyr-701-phosphorylated form of Statla (20) . Although Statlf3 also becomes phosphorylated, the mobility of the phosphorylated form is indistinguishable from that of the unphosphorylated form. To assess the specificity of the anti-phospho-Statl serum, this blot was then stripped and reprobed with the anti-phospho-Statl serum. This antibody recognized no bands in untreated cells (Fig. 1, lane 3) . By contrast, in the IFN-atreated cells, it recognized bands corresponding to phosphorylated Statla and phosphorylated Statlj3, with a 10-fold greater sensitivity than that of antibody 91/84 (Fig. 1, lane 4 (Fig. 3) . We considered whether Statl was phosphorylated on tyrosine in response to IL-2 treatment. Immunoprecipitation with antibody 91C, which recognizes the carboxyl terminus of the 91-kDa Statla protein (amino acids 713-738) followed by blotting with anti-phosphotyrosine antibodies allowed the detection in IL-2-treated NKL cells of a band of molecular mass 92 kDa that is identical in mobility to Statla precipitated from IFN-a-treated cells (Fig. 3, lanes 5 and 6) . Given this finding and the fact that the anti-phospho-Statl antibodies recognized a protein of identical mobility from IL-2-treated NKL cells by Western blotting (Fig. 2A) , we conclude that Statl is phosphorylated on tyrosine in response to IL-2. The magnitude of tyrosine phosphorylation of Statl in response to IL-2 is consistently less than that seen with stimulation by IFN-a. This may reflect the fact that the 94-kDa and 95-kDa proteins appear to be the principal Stats phosphorylated in response to IL-2.
We next considered whether Stat2 was phosphorylated in response to IL-2. Immunoprecipitation with antibody 113, which recognizes a unique segment of Stat2, followed by blotting with anti-phosphotyrosine antibodies revealed a 113-kDa band from IFN-a-treated cells that represents Stat2 (Fig. 3, lane 12) . Of note, Statla (91 kDa) and Statl3 (84 kDa) were coprecipitated by antibody 113. By contrast, no phosphotyrosine-containing protein was immunoprecipitated by antibody 113 from IL-2-treated NKL cells (Fig. 3, lane 11) , suggesting that this protein is not phosphorylated on tyrosine in response to IL-2. To examine the potential role of Stat3 in IL-2-induced signaling, immunoprecipitation was carried out with antibody 91N, followed by blotting with the antiphosphotyrosine antibody. The 91N antibody was raised to the amino terminus of Statl (amino acids 2-66), a region that is highly conserved in Stat3 (24) . This antibody can immunoprecipitate Statl only weakly, but it is very effective at immunoprecipitating Stat3 (29) . Antibody 91N precipitated an 89-kDa, tyrosine-phosphorylated protein from IL-2-treated cells that represents Stat3 (Fig. 3, lane 2 (91N; lanes 1-3) , amino acids 713-738 (91C; lanes 4-6), and amino acids 504-596 (91SH2; lanes 7-9) and against Stat2 amino acids 671-806 (113; lanes 10-12).
factor stimulation of neuroblastoma cells (29) . No such protein was detected in IFN-a-treated cells (Fig. 3, lane 3) (Fig. 3, lane 9) . By contrast, antibody 91SH2 did precipitate from IL-2-treated NKL cells but not from untreated cells proteins of 94 and 95 kDa that were detected upon blotting with anti-phosphotyrosine antibodies (Fig. 3, lane 8 anti-phospho-Statl antiserum, p94 appears to be more prominent than p95 in IL-2-treated cells (Fig. 2) . Following immunoprecipitation with the 91SH2 antibody and blotting with anti-phosphotyrosine antibodies, p95 often appears slightly more prominent (Fig. 3) . This may reflect a difference in the relative affinities of the anti-phospho-Statl antiserum and the anti-phosphotyrosine antibodies for the phosphorylation sites of p94 and p95. Alternatively, p95 may have other phosphorylated tyrosine residues in addition to that recognized by the anti-phospho-Statl antiserum, and this may lead to a stronger signal on the anti-phosphotyrosine Western blot.
Nuclear Translocation and DNA Binding. Upon activation by tyrosine phosphorylation, Stat proteins may translocate to the nucleus where they can bind to specific DNA sequences. Cellular fractionation followed by. anti-phospho-Statl Western blotting of NKL cells treated with IL-2 revealed the presence of all of the bands identified by Western blots of whole-cell extracts in the nucleus (Fig. 4A) . Immunocytochemistry with the anti-phospho-Statl antibody also revealed nuclear staining of NKL cells after IL-2 treatment, but not in untreated cells (data not shown). Given the finding that Jak kinases are activated in the cytoplasm by IL-2 and the fact that unphos- phorylated Stat proteins are located in the cytoplasm in other systems, this suggests that IL-2 induces the tyrosine phosphorylation and translocation of Statla, StatlI3 and the 94-and 95-kDa proteins. This ability to localize in the nucleus upon tyrosine phosphorylation further supports the idea that the 94-and 95-kDa proteins are Stat family members. To assess the ability of these Stat proteins to bind DNA, electrophoretic mobility-shift assays were performed (Fig. 4B) . The probe used was a DNA sequence from the IFN-responsive factor 1 gene promoter (AGCCTGATTTCCCCGAAATGACGGC) (31) that can bind homodimers of Statla, homodimers of Stat3, and heterodimers of Statla and Stat3 (29) . IL-2 treatment of NKL cells led to the inducible formation of three complexes bound to this DNA element (Fig. 4B, lanes 2) . Small amounts of these complexes were detected occasionally in untreated cells (Fig. 4B, lane 1) . All of the protein-DNA complexes could be abolished by the presence of excess unlabeled DNA probe (Fig. 4B, lane 11) , suggesting that they represented specific binding complexes. We considered whether Statla was a component of one of these protein-DNA complexes. Antibodies specific for the carboxyl terminus of Statla disrupted complex I, suggesting that Statla is present in this complex (Fig. 4B, lane 3) . Antibodies to the amino terminus of Statl that also recognize Stat3 also abolished complex I and, in addition, led to the formation of supershifted complex A (Fig. 4B, lane 4) . This pattern of complex inhibition and supershift formation by these antibodies is identical to that seen when Statl and Stat3 are bound to the probe (29) , suggesting the participation of Stat3 in the binding to this DNA sequence. Anti-phospho-Statl antibodies led to a decrease in complexes I and II and the formation of supershifted complex C (Fig. 4B, lane 6) . This suggested that one or more proteins recognized by anti-phospho-Statl were present in complexes I and II, although Statl itself appeared to be in complex III. Antibodies to the SH2 domain of Statl led to the formation of supershifted complex B (Fig. 4B, lane 5) . This antibody does not supershift complexes from IFN-a-treated cells (data not shown), suggesting that Stat proteins other than Statl that are recognized by this antibody are bound to the DNA probe. Taken together, the results suggest that p94 and/or p95 are likely to be present in protein-DNA complexes I and II. Antibodies to Stat2, -4, -5, and -6 (Fig. 4B, lanes 7-10) neither inhibited complex formation nor supershifted the protein-DNA complexes detected in IL-2-treated cells, suggesting that these Stat proteins were not present in the protein-DNA complexes. We conclude that Statl, Stat3, and the two Stat proteins p94 and p95 not only become phosphorylated and translocate to the nucleus in response to IL-2 but that they participate in specific DNA-binding complexes, as well. Identical findings were observed in activated human T lymphocytes stimulated with IL-2 (data not shown). Similar DNA-binding complexes could be detected with a probe containing a consensus IFN-y-activation site, although nonspecific binding to that probe was greater (data not shown).
DISCUSSION
We have demonstrated that the interaction of IL-2 with its receptor on either PHA-stimulated peripheral blood T cells or on an NK cell line leads to the tyrosine phosphorylation and nuclear translocation of a set of DNA-binding proteins. These proteins include Statla, Statlf3, and Stat3, which have been shown to be phosphorylated in response to a number of cytokines. In addition, two other proteins of molecular masses 94 and 95 kDa are also phosphorylated in response to IL-2. On the basis of the immunoprecipitation experiments, these proteins share antigenic similarity to Statl in the SH2 domain, and from the Western-blotting experiments, they share similarity to the phosphorylation site of Statl. They differ from Statl, however, in their mobility on SDS/polyacrylamide gels, their precipitation by antibodies raised to the SH2 domain of Statl, their lack of precipitation by antibodies raised to the carboxyl terminus of Statl, and their distinct characteristics in DNAbinding assays. Three Stat proteins have been described recently, and we considered whether p94 and p95 could be Stat4, StatS, or Stat6 (26) (27) (28) . Antibodies to Stat4, -5, and -6 did not immunoprecipitate tyrosine-phosphorylated proteins from IL-2-treated cells (data not shown), nor did they alter the DNA binding of nuclear extracts from IL-2-treated cells (Fig. 4B) . Thus, p94 and p95 may be members of the Stat family, though p94 and p95 may be differentially modified forms of the same protein. p94 and p95 appear to be the predominant Stat proteins phosphorylated in T lymphocytes or NK cells in response to IL-2 and may have a major role in determining the genes that are activated in response to IL-2.
Given that multiple cytokines lead to the activation of Jak kinases and the phosphorylation of Stat proteins, a key question concerns how a cytokine leads to specific responses in a particular cell. Multiple levels of control can be envisioned. The presence of a particular ligand-binding a chain on a cell will determine if its cognate cytokine will bind to that cell. The presence of particular 13 and y subunits that can interact with a specific a chain may determine which Jak kinases are activated by cytokine binding. The individual Jak kinase family members may have restricted specificity in terms of Stat proteins that they can phosphorylate. For example, the phosphorylation of p94 and p95 which occurs after IL-2 treatment does not occur in response to IFN-a. This may reflect the specificity of Jak-3, which is not activated in response to IFN (32) . Thus, the specific combination of Stat proteins that become phosphorylated at a given time will likely determine the particular target genes that become activated. Finally, cellor tissue-specific restriction of other regulators of gene activation, such as transcription factors that may function in concert with Stat proteins or the methylation of particular genes, may control cell-specific responses to a given cytokine.
It has recently been shown that the f3 and y subunits of the IL-2 receptor interact with Jak-1 and Jak-3, respectively (33, 34) . It is also known that heterodimerization of the cytoplasmic domains of the 03 and y chains is necessary for IL-2 signaling (3, 4) . Taken together, these results suggest that IL-2 induces dimerization of the 3 and -y subunits, leading to phosphorylation and activation of Jak-1 and Jak-3. The present study provides evidence for the subsequent steps of IL-2-induced signal transduction. Five Stat proteins-Statla, Statlf3, Stat3, and the Stat proteins described here, p94 and p95-are phosphorylated on tyrosine and translocate to the nucleus, where they can bind to specific DNA sequences and may lead to the transcriptional activation of genes that contain these DNA sequences within their promoter. That each of these five proteins has distinct kinetics of phosphorylation raises the possibility that different DNA-binding complexes may form over time. This may allow these proteins to participate in the sequential activation of genes over many hours following stimulation by IL-2. Studies of the c-fos protooncogene have suggested that the serum-response element can mediate IL-2-induced gene activation (35) . The present study suggests that DNA sequences to which Stat proteins can bind also may be important for the transcriptional activation of genes in response to IL-2.
The identification of Stat proteins activated in response to IL-2 will allow a further analysis of the physiological effects of this cytokine, including the identification of genes that are transcriptionally activated in response to IL-2. Such knowledge may shed light on T-cell and NK-cell activation and proliferation, as well as on defects in lymphocyte signaling. It is already known that at least one form of severe combined immunodeficiency in humans, in which there is diminished lymphocyte proliferation in response to IL-2, is associated with a point mutation in the 'y subunit of the IL-2 receptor that decreases the association of this subunit with Jak-3 (33) . Recent evidence also suggests that IL-2, IL-4, and IL-7, all of which share a common oy chain in their receptors and activate Jak-3, may prevent the induction of anergy (36) . Thus, understanding these signaling components may shed light on such processes as immunodeficiency states, immune suppression, and lymphoid malignancies.
